Olema Pharmaceuticals Business Summary

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company that generates revenue through strategic licensing agreements, research collaborations, and future product commercialization, though it currently reports zero product revenue as its pipeline remains in development. The company operates primarily in the oncology segment, focusing on the discovery and development of targeted therapies for women’s cancers, specifically estrogen receptor-positive (ER+) breast cancer. Its flagship asset, palazestrant (OP-1250), is a proprietary oral complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently advancing through pivotal Phase 3 clinical trials (OPERA-01 and OPERA-02). Olema competes directly with major pharmaceutical players including AstraZeneca, Roche, Arvinas, and Stemline Therapeutics (Menarini Group). Within this landscape, Olema positions itself as a developer of a potential best-in-class oral endocrine therapy designed to overcome resistance mechanisms that limit current standards of care like fulvestrant. The company is led by President and CEO Sean P. Bohen, M.D., Ph.D., who previously served as Executive Vice President of Global Medicines Development and CMO at AstraZeneca; as of January 30, 2026, Dr. Bohen also serves as the interim Principal Financial Officer following the departure of CFO Shane Kovacs. The founding team includes Cyrus Harmon, Ph.D., who serves on the Board of Directors, and Peter Kushner, Ph.D., a renowned ER biology expert who transitioned from CSO to Senior Research Fellow. Other key executives include Chief Medical Officer Naseem Zojwalla, M.D., Chief Discovery and Non-Clinical Development Officer David C. Myles, Ph.D., and Chief Legal Officer Shawnte M. Mitchell, J.D. Olema is backed by a sophisticated roster of institutional investors, including Bain Capital Life Sciences, Paradigm BioCapital Advisors, and BVF Partners. The Board of Directors is chaired by Ian T. Clark, former CEO of Genentech, and includes industry veterans such as Dr. Sandra Horning and Yi Larson.